| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma |
|
Medicine details |
|
| Medicine name | cabozantinib (Cabometyx®) |
| Formulation | 20mg, 40mg, 60mg film-coated tablet |
| Reference number | 1694 |
| Indication | As monotherapy for the treatment of hepatocellular carcinoma in adults who have been previously treated with sorafenib |
| Company | Ipsen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/12/2018 |
| NICE guidance | TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma |